The Sato Lab (Kei Sato)
XBB.1.5 monovalent mRNA vaccine has been available since September 2023. However, we found that breakthrough infection with XBB subvariants, including XBB.1.5, does not efficiently induce humoral immunity against the infecting XBB subvariants. e.g., 2/ https://x.com/SystemsVirology/status/1701413583161266324?s=20
The Sato Lab (Kei Sato)
BREAKING🔔 The 27th paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We elucidated the virological characteristics of new SARS-CoV-2 variant of interest, EG.5 (aka #Eris) Please RT🔥 1/ https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00553-4/fulltext